Last reviewed · How we verify
CTGel/ BPO Wash
CTGel/BPO Wash is a topical formulation combining clindamycin and benzoyl peroxide to reduce acne-causing bacteria and inflammation on the skin.
CTGel/BPO Wash is a topical formulation combining clindamycin and benzoyl peroxide to reduce acne-causing bacteria and inflammation on the skin. Used for Acne vulgaris.
At a glance
| Generic name | CTGel/ BPO Wash |
|---|---|
| Also known as | Veltin |
| Sponsor | Stiefel, a GSK Company |
| Drug class | Topical antibiotic combination with antimicrobial agent |
| Target | Cutibacterium acnes (bacterial target); bacterial ribosome (clindamycin); reactive oxygen species generation (benzoyl peroxide) |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
Benzoyl peroxide acts as an antimicrobial and keratolytic agent that kills Cutibacterium acnes (formerly Propionibacterium acnes) and reduces sebum production. Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis. Together, they provide synergistic antibacterial and anti-inflammatory effects for acne treatment.
Approved indications
- Acne vulgaris
Common side effects
- Skin irritation
- Dryness
- Erythema
- Peeling
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CTGel/ BPO Wash CI brief — competitive landscape report
- CTGel/ BPO Wash updates RSS · CI watch RSS
- Stiefel, a GSK Company portfolio CI